Excelsior Correspondent
CHANDIGARH, Oct 4: CSIR- Institute of Microbial Technology (IMTECH), a premier microbial Institute under the aegis of Ministry of Science and Technology, Government of India, is organizing a three- day international conference IMTechCon 2017 from today.
The aim of this meet is to engage industry and academic leaders to discuss current unmet medical needs globally. The conference was presided over by Governor of Haryana, Prof Kaptan Singh Solanki who suggested that such close interactions will pave path to forge new R & D partnership and alliances between industry and research institutions and lead to more product/ technology development output.
Also present on this occasion were Stef Hylen, MD, Chief Operating Officer, Janssen R&D, Pinaki Panigrahi, MD, PhD Professor, University of Nebraska, Altaf Lal, Senior Advisor for Global Health and Innovation, Sunpharma, India and Christopher Gibbins, Canadian Consul General in Chandigarh.
IMTechCon 2017 shall see more than 35 speakers and panelists present their ideas and views across three days in the areas of challenges and opportunities in Antimicrobial Drug Discovery, Human Microbiome in Health and Disease, Future of Biotherapeutics and Ecosystem for New Innovations & Biotech Startups. Distinguished panel of speakers at IMTechCon during next two days include policy makers: Dr Girish Sahni, Director General, CSIR, Dr Soumya Swaminathan, Director General, ICMR and leaders from renowned multinationals in the Pharma sector like Sun Pharma, DaiichiSankyo, Cadila, Epygen, Biocon, etc. This event shall enable engagement with industry and academia leaders for addressing India’s critical healthcare challenges.
Speaking at the occasion Dr Anil Koul, Director, IMTECH said, “We will take this opportunity to showcase our products and technologies at IMTEHC along with ongoing efforts in the field of biomedical research for unmet medical needs.
CSIR-IMTECH signed agreements with University of British Columbia, National Institute of Pharmaceutical Education, Asian Institute of Public Health, Nectar Life Sciences Private Ltd and Oniosome Healthcare Private Limited for giving a major thrust to help discover new drugs and technologies in a collaborative mode.
Dr Stef Heylen, Chief Operating Officer, Janssen R&D said, “We have made great advances in recent years with the approval of new TB medicines and much more needs to be done.”
Dr Pinaki Panigrahi, Professor of Epidemiology and Pediatrics, University of Nebraska Medical Center, College of Public Health, USA, described how the diversity in a vast country can be used as a platform for discovery that ultimately improves population health.
Follow our WhatsApp channel
